CN111529535A - 用于治疗肥胖症的化合物和其使用方法 - Google Patents

用于治疗肥胖症的化合物和其使用方法 Download PDF

Info

Publication number
CN111529535A
CN111529535A CN202010540739.7A CN202010540739A CN111529535A CN 111529535 A CN111529535 A CN 111529535A CN 202010540739 A CN202010540739 A CN 202010540739A CN 111529535 A CN111529535 A CN 111529535A
Authority
CN
China
Prior art keywords
triptolide
leptin
alkyl
mice
obese
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010540739.7A
Other languages
English (en)
Chinese (zh)
Inventor
U·奥兹坎
J·马兹欧伯
R·马兹斯柴克
I·卡奇尔
S·卡比
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Boston Childrens Hospital
Original Assignee
General Hospital Corp
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49304418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN111529535(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by General Hospital Corp, Boston Childrens Hospital filed Critical General Hospital Corp
Publication of CN111529535A publication Critical patent/CN111529535A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202010540739.7A 2012-09-27 2013-09-26 用于治疗肥胖症的化合物和其使用方法 Pending CN111529535A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261706153P 2012-09-27 2012-09-27
US61/706,153 2012-09-27
CN201380061929.9A CN104822374A (zh) 2012-09-27 2013-09-26 用于治疗肥胖症的化合物和其使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380061929.9A Division CN104822374A (zh) 2012-09-27 2013-09-26 用于治疗肥胖症的化合物和其使用方法

Publications (1)

Publication Number Publication Date
CN111529535A true CN111529535A (zh) 2020-08-14

Family

ID=49304418

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202010540726.XA Pending CN111529534A (zh) 2012-09-27 2013-09-26 用于治疗肥胖症的化合物和其使用方法
CN201380061929.9A Pending CN104822374A (zh) 2012-09-27 2013-09-26 用于治疗肥胖症的化合物和其使用方法
CN202010540739.7A Pending CN111529535A (zh) 2012-09-27 2013-09-26 用于治疗肥胖症的化合物和其使用方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN202010540726.XA Pending CN111529534A (zh) 2012-09-27 2013-09-26 用于治疗肥胖症的化合物和其使用方法
CN201380061929.9A Pending CN104822374A (zh) 2012-09-27 2013-09-26 用于治疗肥胖症的化合物和其使用方法

Country Status (21)

Country Link
US (6) US9968575B2 (enExample)
EP (3) EP2900230B1 (enExample)
JP (2) JP6480864B2 (enExample)
CN (3) CN111529534A (enExample)
AU (3) AU2013323528B2 (enExample)
BR (1) BR112015006848A2 (enExample)
CA (2) CA2886393C (enExample)
CY (1) CY1121166T1 (enExample)
DK (1) DK2900230T3 (enExample)
ES (1) ES2696626T3 (enExample)
HR (1) HRP20181879T1 (enExample)
HU (1) HUE040496T2 (enExample)
LT (1) LT2900230T (enExample)
PL (1) PL2900230T3 (enExample)
PT (1) PT2900230T (enExample)
RS (1) RS58010B1 (enExample)
RU (2) RU2768868C2 (enExample)
SI (1) SI2900230T1 (enExample)
SM (1) SMT201800604T1 (enExample)
TR (1) TR201815668T4 (enExample)
WO (1) WO2014052583A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116133656A (zh) * 2021-09-09 2023-05-16 君德(新加坡)实验室有限公司 含脂肪酶抑制剂的高吸收性水凝胶

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111529534A (zh) 2012-09-27 2020-08-14 儿童医学中心公司 用于治疗肥胖症的化合物和其使用方法
CN117357538A (zh) * 2014-03-26 2024-01-09 儿童医学中心公司 用于治疗肥胖症的雷公藤红素和衍生物
US20170209408A1 (en) * 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CN105985401B (zh) * 2015-02-16 2020-10-09 上海华拓医药科技发展有限公司 一种雷公藤红素衍生物、其制备方法及用途
JP7034078B2 (ja) * 2015-10-23 2022-03-11 イーアールエックス ファーマシューティカルズ インコーポレイテッド セラストロールの類似体
CN106905404B (zh) * 2017-01-13 2019-08-27 广东工业大学 熊果酸衍生物及其制备方法和应用
KR102470686B1 (ko) * 2022-06-07 2022-11-23 서울대학교산학협력단 디메틸제일아스테럴을 포함하는 대사성 질환 예방 또는 치료용 약학 조성물
CN119431489A (zh) * 2024-11-13 2025-02-14 肇源县总医院 一种雷公藤红素衍生物及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101279995A (zh) * 2007-04-03 2008-10-08 烟台靶点药物研究有限公司 一种雷公藤红素盐及其制备方法与用途
CN101352444A (zh) * 2008-09-11 2009-01-28 中国科学院广州生物医药与健康研究院 雷公藤红素在制药中的新应用
CN101704874A (zh) * 2009-11-26 2010-05-12 中国药科大学 五环三萜及其衍生物的二甲双胍盐、其制备方法及医药用途
CN101939022A (zh) * 2007-11-14 2011-01-05 安米林药品公司 治疗肥胖以及肥胖相关疾病和病症的方法

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
EP0832220A1 (en) 1995-06-07 1998-04-01 Amgen Inc. Ob protein compositions and method
KR19990028388A (ko) 1995-06-30 1999-04-15 피터 지. 스트링거 당뇨병 치료 방법
DK0865294T3 (da) 1995-08-17 2004-06-28 Amgen Inc Fremgangsmåder til reduktion eller bibeholdelse af reducerede niveauer afblodlipider under anvendelse af OB-proteinpræparater
US5650167A (en) 1995-11-16 1997-07-22 Dawa Incorporated Method and composition for treating hepatitis B
DE69638119D1 (de) 1995-11-22 2010-03-11 Amgen Inc Verfahren zur Erhöhung der mageren Fleischmasse mit Fettleibigkeitsprotein (OB) Zusammensetzungen
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
AU2670897A (en) 1996-04-04 1997-10-29 Amgen, Inc. Fibulin pharmaceutical compositions and related methods
WO1998008512A1 (en) 1996-08-30 1998-03-05 Amgen Inc. Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor
CZ90999A3 (cs) 1996-09-20 1999-06-16 Hoechst Aktiengesellschaft Farmaceutický přípravek obsahující antagonistu leptinu vhodný pro léčení inzulínové rezistence u diabetes mellitus II. typu
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
US5880116A (en) * 1996-12-13 1999-03-09 Neurocal International Use of celastrol to treat alzheimer's disease
EP0954588B1 (en) 1996-12-20 2007-01-17 Amgen Inc. Ob fusion protein compositions and methods
DE69807679T2 (de) 1997-04-17 2003-07-31 Amgen Inc., Thousand Oaks Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
CA2293504A1 (en) 1997-06-06 1998-12-10 Valur Emilsson Use of leptin antagonists for the treatment of diabetes
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
JP4199421B2 (ja) 1998-08-10 2008-12-17 アムジエン・インコーポレーテツド デキストラン−レプチン結合体、医薬組成物および関連方法
EP1118001A1 (en) 1998-10-02 2001-07-25 Amgen Inc. Method to determine a predisposition to leptin treatment
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
ATE323766T1 (de) 1999-02-12 2006-05-15 Amgen Inc Glykosylierte leptinzusammensetzungen und zugehörige verfahren
ES2350924T3 (es) 2001-10-22 2011-01-28 Amgen, Inc. Uso de leptina para el tratamiento de la lipoatrofia humana y método para determinar la predisposición a dicho tratamiento.
JP2006508182A (ja) 2002-10-21 2006-03-09 メタプロテオミクス， エルエルシー 炎症応答と関連した病理学的状態を処置または抑制する組成物。
AU2003290563A1 (en) 2002-10-31 2004-05-25 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
RU2346688C2 (ru) * 2002-12-06 2009-02-20 Фиброген, Инк. Регулирование содержания жира
WO2005069415A1 (ja) 2004-01-16 2005-07-28 Mitsubishi Materials Corporation 燃料電池用セパレータ、セパレータの製造方法および固体酸化物形燃料電池
US20060253100A1 (en) * 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
JP4169777B2 (ja) 2005-09-30 2008-10-22 森永乳業株式会社 インスリン抵抗性改善剤
EP1948191B1 (en) 2005-11-01 2013-01-16 The Regents of the University of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
US20090131384A1 (en) 2006-03-22 2009-05-21 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with er stress
US20110263693A1 (en) * 2006-03-31 2011-10-27 Dana-Farber Cancer Institute, Inc. Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
WO2008021210A2 (en) 2006-08-11 2008-02-21 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
WO2008020622A1 (en) * 2006-08-17 2008-02-21 Kyorin Pharmaceutical Co., Ltd. NOVEL THIENO[2,3-d]PYRIMIDINE COMPOUND
CN101686951A (zh) * 2006-11-13 2010-03-31 纽约市哥伦比亚大学托管会 治疗糖尿病的选择性蛋白酶体抑制物
US7776894B2 (en) 2007-08-17 2010-08-17 Burnham Institute For Medical Research Compositions and methods for inhibiting growth and metastasis of melanoma
CN101434635B (zh) * 2007-11-16 2012-05-16 上海华拓医药科技发展股份有限公司 一类具抗肿瘤活性的水溶性酚性三萜化合物及其制备方法
US20110218143A1 (en) * 2007-11-20 2011-09-08 University Of Florida Research Foundation Compositions and methods for tissue repair
CA2712593A1 (en) 2008-02-01 2009-08-13 The Scripps Research Institute Methods for treating a condition characterized by dysfunction in protein homeostasis
WO2010119674A1 (ja) * 2009-04-17 2010-10-21 国立大学法人広島大学 レプチン抵抗性を改善および／または予防するための薬学的組成物、並びにその使用
AU2011240690C1 (en) 2010-04-12 2014-11-06 Reata Pharmaceuticals Holdings, LLC Method of treating obesity using antioxidant inflammation modulators
CN101805390B (zh) 2010-04-13 2012-07-18 暨南大学 一种雷公藤红素衍生物及其用途
CN102309494A (zh) * 2010-07-01 2012-01-11 嘉兴学院 扁蒴藤素作为炎性细胞因子抑制剂的医药用途
CA2808359C (en) 2010-08-23 2019-09-24 Suzhou Neupharma Co., Ltd. Analogs of celasterol and pharmaceutical compositions comprised thereof
WO2012036293A1 (ja) * 2010-09-17 2012-03-22 武田薬品工業株式会社 糖尿病治療剤
KR101180387B1 (ko) 2011-11-21 2012-09-10 동국대학교 산학협력단 엣지 추출을 위한 이미지 센서 및 이를 이용한 엣지 이미지 생성 방법.
HK1209035A1 (en) 2012-05-25 2016-03-24 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
CN111529534A (zh) 2012-09-27 2020-08-14 儿童医学中心公司 用于治疗肥胖症的化合物和其使用方法
CN103524592B (zh) 2013-09-27 2015-08-05 安徽医科大学 一种雷公藤红素衍生物、该衍生物的生物盐及其制备方法与用途
US9601471B2 (en) 2015-04-23 2017-03-21 Apple Inc. Three layer stack structure

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101279995A (zh) * 2007-04-03 2008-10-08 烟台靶点药物研究有限公司 一种雷公藤红素盐及其制备方法与用途
CN101939022A (zh) * 2007-11-14 2011-01-05 安米林药品公司 治疗肥胖以及肥胖相关疾病和病症的方法
CN101352444A (zh) * 2008-09-11 2009-01-28 中国科学院广州生物医药与健康研究院 雷公藤红素在制药中的新应用
CN101704874A (zh) * 2009-11-26 2010-05-12 中国药科大学 五环三萜及其衍生物的二甲双胍盐、其制备方法及医药用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JIEUN LEE, ET AL.: "The Effect of Celastrol on Metabolic Disturbances and Renal Injury in High Fat Diet-induced Obesity Mice", 《THE KOREAN JOURNAL OF NEPHROLOGY》, 3 December 2011 (2011-12-03) *
刘国卿: "《高等药科院校教材 药理学》", 中国医药科技出版社, pages: 32 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116133656A (zh) * 2021-09-09 2023-05-16 君德(新加坡)实验室有限公司 含脂肪酶抑制剂的高吸收性水凝胶

Also Published As

Publication number Publication date
JP6743211B2 (ja) 2020-08-19
CN111529534A (zh) 2020-08-14
US9968575B2 (en) 2018-05-15
US20210275482A1 (en) 2021-09-09
RU2018112067A3 (enExample) 2021-06-24
RU2015115696A (ru) 2016-11-20
RU2650646C2 (ru) 2018-04-16
EP2900230B1 (en) 2018-08-15
ES2696626T3 (es) 2019-01-17
SMT201800604T1 (it) 2019-01-11
US11045439B2 (en) 2021-06-29
CA2886393A1 (en) 2014-04-03
EP3434268B1 (en) 2022-04-20
JP6480864B2 (ja) 2019-03-13
EP2900230A1 (en) 2015-08-05
US20180185314A1 (en) 2018-07-05
CA3030272A1 (en) 2014-04-03
EP3434268A1 (en) 2019-01-30
AU2016247206B2 (en) 2018-08-02
LT2900230T (lt) 2019-01-10
RU2018112067A (ru) 2019-03-07
RU2768868C2 (ru) 2022-03-25
SI2900230T1 (sl) 2019-01-31
EP4082541A1 (en) 2022-11-02
AU2013323528B2 (en) 2016-11-10
US20150250753A1 (en) 2015-09-10
US10653654B2 (en) 2020-05-19
CA3030272C (en) 2021-09-28
US12064408B2 (en) 2024-08-20
US20170304245A1 (en) 2017-10-26
RS58010B1 (sr) 2019-02-28
JP2015531376A (ja) 2015-11-02
CY1121166T1 (el) 2020-05-29
WO2014052583A1 (en) 2014-04-03
DK2900230T3 (en) 2018-11-12
US9925161B2 (en) 2018-03-27
HRP20181879T1 (hr) 2019-02-08
BR112015006848A2 (pt) 2018-05-22
US20250161252A1 (en) 2025-05-22
CN104822374A (zh) 2015-08-05
HUE040496T2 (hu) 2019-03-28
AU2018256619A1 (en) 2018-11-22
PT2900230T (pt) 2018-11-26
AU2016247206A1 (en) 2016-11-10
PL2900230T3 (pl) 2019-02-28
HK1213190A1 (en) 2016-06-30
AU2018256619B2 (en) 2020-07-23
US20210008019A1 (en) 2021-01-14
CA2886393C (en) 2019-02-26
AU2013323528A1 (en) 2015-04-09
TR201815668T4 (tr) 2018-11-21
JP2019070052A (ja) 2019-05-09

Similar Documents

Publication Publication Date Title
US12064408B2 (en) Compounds for the treatment of obesity and methods of use thereof
RU2706239C2 (ru) Целастрол и его производные для лечения ожирения
JP6672157B2 (ja) 肥満を処置するための化合物およびその使用方法
HK40083451A (en) Compounds for the treatment of obesity and methods of use thereof
HK40034040A (en) Compounds for the treatment of obesity and methods of use thereof
HK40034039A (en) Compounds for the treatment of obesity and methods of use thereof
HK40003238A (en) Compounds for the treatment of obesity and methods of use thereof
HK40003238B (en) Compounds for the treatment of obesity and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40034040

Country of ref document: HK